Literature DB >> 11280800

The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras.

E Cohen-Jonathan1, S M Evans, C J Koch, R J Muschel, W G McKenna, J Wu, E J Bernhard.   

Abstract

Many tumors contain extensive regions of hypoxia. Because hypoxic cells are markedly more resistant to killing by radiation, repeated attempts have been made to improve the oxygenation of tumors to enhance radiotherapy. We have studied the oxygenation of tumor xenografts in nude mice after treatment with the farnesyltransferase inhibitor L744,832. Hypoxia was assessed by measuring the binding of the hypoxic cell marker pentafluorinated 2-nitroimidazole. We show that xenografts from two tumor cell lines with mutations in H-ras had markedly improved oxygenation after farnesyltransferase treatment. In contrast, xenografts from two tumors without ras mutations had equivalent hypoxia regardless of treatment. The effect on tumor oxygenation could be detected at 3 days and remained after 7 days of treatment. These results indicate that treatment with farnesyltransferase inhibitors can alter the oxygenation of certain tumors and suggest that such treatment might be useful in the radiosensitization of these tumors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11280800

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

Review 1.  Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.

Authors:  Shom Goel; Andus Hon-Kit Wong; Rakesh K Jain
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

2.  CAAX-box protein, prenylation process and carcinogenesis.

Authors:  Juehua Gao; Jie Liao; Guang-Yu Yang
Journal:  Am J Transl Res       Date:  2009-05-25       Impact factor: 4.060

3.  Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors.

Authors:  Norbert Berndt; Saïd M Sebti
Journal:  Nat Protoc       Date:  2011-10-27       Impact factor: 13.491

Review 4.  Normalization of the vasculature for treatment of cancer and other diseases.

Authors:  Shom Goel; Dan G Duda; Lei Xu; Lance L Munn; Yves Boucher; Dai Fukumura; Rakesh K Jain
Journal:  Physiol Rev       Date:  2011-07       Impact factor: 37.312

5.  Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas.

Authors:  Mara Gilardi; Zhiyong Wang; Marco Proietto; Anastasia Chillà; Juan Luis Calleja-Valera; Yusuke Goto; Marco Vanoni; Matthew R Janes; Zbigniew Mikulski; Antonio Gualberto; Alfredo A Molinolo; Napoleone Ferrara; J Silvio Gutkind; Francis Burrows
Journal:  Mol Cancer Ther       Date:  2020-07-29       Impact factor: 6.261

Review 6.  Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy.

Authors:  Amit Maity; Eric J Bernhard
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

Review 7.  Isoprenoids and related pharmacological interventions: potential application in Alzheimer's disease.

Authors:  Ling Li; Wei Zhang; Shaowu Cheng; Dongfeng Cao; Marc Parent
Journal:  Mol Neurobiol       Date:  2012-03-15       Impact factor: 5.590

8.  Targeting protein prenylation for cancer therapy.

Authors:  Norbert Berndt; Andrew D Hamilton; Saïd M Sebti
Journal:  Nat Rev Cancer       Date:  2011-10-24       Impact factor: 60.716

9.  1-Hydroxy-ethyl-2-methyl-5-nitro-imidazolium 3-carb-oxy-4-hydroxy-benzene-sulfonate.

Authors:  Bo Yang
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-06-25

10.  Tumor vascular changes mediated by inhibition of oncogenic signaling.

Authors:  Naseer Qayum; Ruth J Muschel; Jae Hong Im; Lukxmi Balathasan; Cameron J Koch; Sonal Patel; W Gillies McKenna; Eric J Bernhard
Journal:  Cancer Res       Date:  2009-07-21       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.